US audience sizing
Vyzulta & Lumigan patients
Estimated US patients currently treating with either brand
450,000 – 550,000
Vyzulta
latanoprostene bunod
75,000 – 110,000
est. total US patients · Growing — nearly 3× since 2020
| Year | Patients | Claims | Spend |
|---|---|---|---|
| 2020 | 28,139 | 101,073 | $37.6M |
| 2022 | 57,544 | 206,403 | $86.5M |
| 2024 | 75,825 | 292,207 | $128.3M |
Medicare Part D beneficiaries
Lumigan
bimatoprost, branded
340,000 – 450,000
est. total US patients · Declining — losing share to generics
| Year | Patients | Claims | Spend |
|---|---|---|---|
| 2020 | 382,851 | 1,718,576 | $633.5M |
| 2022 | 366,333 | 1,606,849 | $701.3M |
| 2024 | 336,870 | 1,407,999 | $647.2M |
Medicare Part D beneficiaries
Source: CMS Medicare Part D Spending by Drug (data.cms.gov), through 2024. Totals beyond Medicare are estimates; commercial/cash detail requires IQVIA or Symphony claims data.